This phenotype also correlates with the presence of the LRRK2 G2019S mutation, since genetically corrected L2-PD DAns displayed percentages of apoptotic (cleaved Caspase3-positive) cells similar to controls, and control DAns engineered to carry the LRRK2 G2019S mutation underwent apoptosis at rates close to L2-PD DAns (Fig 2 A–B, see also25). Here, LRRK2 is linked to Parkinson disease.